Literature DB >> 9196143

Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.

S M Ansell1, T M Habermann, P J Kurtin, T E Witzig, M G Chen, C Y Li, D J Inwards, J P Colgan.   

Abstract

PURPOSE: The International Prognostic Factor Index has been shown to predict the outcome of patients with predominantly B-cell lymphomas classified using traditional classifications, including the Working Formulation, but its prognostic importance has not been tested in a cohort of patients with exclusively T-cell lymphomas. This study was conducted to evaluate the prognostic significance of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma (PTCL). PATIENTS AND METHODS: Seventy-eight patients (48 men and 30 women) with PTCL seen at a single institution between 1985 and 1995 were included in the analysis. The morphology and immunocytochemistry of all the original biopsy specimens were reviewed by a single pathologist and classified using the Revised European-American Lymphoma (REAL) classification. The International Prognostic Factor Index, as well as clinical and biochemical parameters, were evaluated by univariate and multivariate analyses to determine their association with patient outcome.
RESULTS: The International Prognostic Factor Index strongly predicted survival when all patients were included in the analysis (P < .001). For patients < or = 60 years, the age-adjusted International Index significantly predicted long-term survival (P = .0218). For patients older than 60 years, the age-adjusted International Index also significantly predicted survival (P = .002). Liver involvement (P = .006) and bone marrow involvement (P = .014) were also significant prognostic factors in the univariate analysis, but only the International Index remained significant in the multivariate analysis (P = .001).
CONCLUSION: The International Prognostic Factor Index, which significantly predicts outcome in patients with aggressive/intermediate-grade B-cell lymphomas, has similar prognostic importance in patients with PTCL.

Entities:  

Mesh:

Year:  1997        PMID: 9196143     DOI: 10.1200/JCO.1997.15.6.2296

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

Review 1.  Treatment of T-cell non-Hodgkin's lymphoma.

Authors:  Andrew M Evens; Ronald B Gartenhaus
Journal:  Curr Treat Options Oncol       Date:  2004-08

2.  Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.

Authors:  Esperanza B Papadopoulos; Miguel-Angel Perales; Jenna D Goldberg; Joanne F Chou; Steven Horwitz; Julie Teruya-Feldstein; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Sergio Giralt; Ann A Jakubowski; Guenther Koehne; Marcel R M van den Brink; James W Young; Zhigang Zhang
Journal:  Leuk Lymphoma       Date:  2012-01-31

Review 3.  Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?

Authors:  Carla Casulo; Steven Horwitz
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

4.  Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8(+) cytotoxic T-cells.

Authors:  Eva Geissinger; Tobias Odenwald; Seung-Sook Lee; Irina Bonzheim; Sabine Roth; Peter Reimer; Martin Wilhelm; Hans Konrad Müller-Hermelink; Thomas Rüdiger
Journal:  Virchows Arch       Date:  2004-07-29       Impact factor: 4.064

5.  Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified.

Authors:  Agustin Avilés; Claudia Castañeda; Natividad Neri; Sergio Cleto; Alejandra Talavera; Martha González; Judith Huerta-Guzmán; M Jesús Nambo
Journal:  Med Oncol       Date:  2008-02-05       Impact factor: 3.064

6.  Activation of T-cell receptor signaling in peripheral T-cell lymphoma cells plays an important role in the development of lymphoma-associated hemophagocytosis.

Authors:  Jun An; Hiroshi Fujiwara; Koichiro Suemori; Toshiyuki Niiya; Taichi Azuma; Kazushi Tanimoto; Toshiki Ochi; Yoshiki Akatsuka; Junichi Mineno; Hidetoshi Ozawa; Fumihiko Ishikawa; Kiyotaka Kuzushima; Masaki Yasukawa
Journal:  Int J Hematol       Date:  2011-01-13       Impact factor: 2.490

7.  Clinicopathological analysis in PTCL-NOS with CADM1 expression.

Authors:  Takeharu Kato; Hiroaki Miyoshi; Seiichiro Kobayashi; Noriaki Yoshida; Yoshitaka Imaizumi; Masao Seto; Kaoru Uchimaru; Yasushi Miyazaki; Koichi Ohshima
Journal:  Virchows Arch       Date:  2017-09-22       Impact factor: 4.064

8.  Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas.

Authors:  Fredrik Ellin; Matthew J Maurer; Line Srour; Umar Farooq; Mats Jerkeman; Joseph M Connors; Karin E Smedby; N Nora Bennani; Stephen M Ansell; Graham W Slack; James R Cerhan; Thomas Relander; Andrew L Feldman; Kerry J Savage
Journal:  Br J Haematol       Date:  2019-03-11       Impact factor: 6.998

Review 9.  Peripheral T-cell lymphoma.

Authors:  Wing Y Au; Raymond Liang
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

10.  Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.

Authors:  Javeed Iqbal; Dennis D Weisenburger; Timothy C Greiner; Julie M Vose; Timothy McKeithan; Can Kucuk; Huimin Geng; Karen Deffenbacher; Lynette Smith; Karen Dybkaer; Shigeo Nakamura; Masao Seto; Jan Delabie; Francoise Berger; Florence Loong; Wing Y Au; Young-Hyeh Ko; Ivy Sng; James Olen Armitage; Wing C Chan
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.